AzTrials
AzTrials

Total Knee ArthroplastyNCT03289247

Tissue Adhaesive in Wound Closure Following Primary Total Knee Arthroplasty

A study testing tissue adhesive (Leukosan®) in people with Total Knee Arthroplasty and Infection, run by Hvidovre University Hospital.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The study's primary objective is to compare the following parameters between wound closure following primary TKA with and without supplement tissue adhesive (Leukosan®): Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
tissue adhesive (Leukosan®)
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
No sites listed yet
Study dates
1 Sep 2015to 31 Dec 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient > 18 years of age.
  • Patients determined to be suitable for primary simultaneous bilateral TKA based on physical exam and medical history including the following:
  • o Osteoarthritis (OA)
  • Patient is skeletally mature.
  • Patient is willing and able to provide written informed consent.
  • Participants must be able to speak and understand Danish
  • Patient is willing and able to cooperate in the required post-operative therapy.
  • Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent.

Who cannot join

  • Patients with previous open knee surgery on either knee (i.e., osteotomy, unicompartemental arthroplasty, osteosynthesis)
  • Patients with previous major trauma to either knee resulting in deformity og scarring.
  • Patients receiving treatment for DVT or PE postoperatively.
  • Patients with known allergy to skin adhesives

About this study

Official title: A Prospective Single-blinded Randomized Controlled Study Evaluating Efficacy of Tissue Adhaesive in Wound Closure Following Primary Total Knee Arthroplasty

The study's primary objective is to compare the following parameters between wound closure following primary TKA with and without supplement tissue adhesive (Leukosan®):

Read the detailed description

Prolonged wound drainage following total joint replacement surgery has been shown to be a predictor of Periprosthetic Joint Infection (PJI) 1-3. Several studies have highlighted this subject, and estimates of the risk of postoperative infection range from 1.3% to 50% among patients with persistent wound drainage 4. Such infections can be one of the most challenging complications following joint replacement surgery and is one of the leading causes of revision surgery following primary hip and knee arthroplasty 5,6.

Several patient-related factors have been associated with delayed wound healing and increased risk of infection following joint replacement surgery. Obesity 4,7, diabetes 8, smoking 9,10 and autoimmune disease 11 have been shown to have a detrimental effect on wound healing. Recently there has also been reports that patients with hypertension 12 have impaired wound healing following total hip arthroplasty (THA) and total knee arthroplasty (TKA).

Surgery related factors such as surgical approach, pneumatic tourniquet time and use of peri-articular local anesthesia have also been shown to have an effect on postoperative wound oozing 9,13.

Finally, several pharmacological factors, such as thromboembolic chemoprophylaxis 4, steroid treatment 9,14 and possibly statins 15,16 might also influence wound healing.

In recent years tissue adhesives for wound closure have been introduced as a replacement or a supplement to conventional closure techniques. Currently very few studies investigate the effect of such tissue adhesives in Total Knee Arthroplasty, and high quality randomized controlled trials (RCT) are lacking.

In this project we wish to:

Evaluate the effect of supplemental wound closure using a high viscosity tissue adhaesive (Leukosan®) in primary TKA with respect to postoperative wound drainage and wound healing.

This project is carried out as a randomized single-blinded controlled trial, in which the clinical outcomes after wound closure following primary bilateral simultaneous TKA with either 1) standard 3-layer closure methods with skin staples or 2) 3-layer closure methods with skin staples supplemented with tissue adhesive (Leukosan®) are compared.

After written informed consent is obtained patients scheduled for a primary bilateral simultaneous TKA will be enrolled in this study and left knee will be randomized to receive either 1) standard 3-layer closure methods with skin staples or 2) 3-layer closure methods with skin staples supplemented with tissue adhesive (Leukosan®), with the opposite treatment on the contralateral knee. All patients will receive AGC total knee prosthesis in both knees (department standard). The standard 3-layer closure consist of: size 2 coated VICRYL® Plus Antibacterial suture for capsule closure, size 2-0 coated VICRYL® Plus Antibacterial suture for subcutaneous tissue closure and stainless steel staples using PROXIMATE® Fixed-Head stapler for cutaneous closure. Wound oozing will be assessed by project nurses during postoperative day 1-3 as well as patient reported wound oozing on postoperative day 3-21. Wound healing will be assessed using ASEPSIS 17,18 score 3 weeks postoperatively.

Range of motion (ROM) will also be recorded at 3 months postoperatively. Allocation of the participants to one of the two treatment groups is done intraoperatively after initial incision has been made. Participants as well as the research coordinator handling the collected questionnaires postoperatively and evaluating wound healing are all unaware of which method was used for skin closure.

Recruitment of participants to this project is expected to begin in September 2015 or as soon as permission from the Regional Ethics Committee and the Danish Data Protections Agency is obtained. A total of 30 participants are to be included at our institution. Recruitment is expected completed after a maximum period of 1.5 years. The project is expected to be completed 1 year after recruitment of the last participant (2018).

Being tested
tissue adhesive (Leukosan®)
Medical subject headings
Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • tissue adhesive (Leukosan®)Device

    Tissue ahaesive

Study groups in NCT03289247
Study groupRoleWhat they receive
RegularNo interventionRegular closure: The standard 3-layer closure is performed using: 1) size 2 coated VICRYL® Plus Antibacterial suture for capsule closure 2) size 2-0 coated VICRYL® Plus Antibacterial suture for subcutaneous tissue closure and 3) stainless steel stables using PROXIMATE® Fixed-Head stapler for cutaneous closure.
Additional tissue adhaesiveExperimentalThe standard 3-layer closure is performed using: 1) size 2 coated VICRYL® Plus Antibacterial suture for capsule closure 2) size 2-0 coated VICRYL® Plus Antibacterial suture for subcutaneous tissue closure and 3) stainless steel stables using PROXIMATE® Fixed-Head stapler for cutaneous closure. tissue adhesive (Leukosan®) is applied on top of the staples according to manufacturer instructions. One layer (one tube) of tissue adhesive is applied following air-drying for 30 seconds, followed by a placement of a second layer with a second layer (one tube), and a second air-drying period of 60 seconds
Receives: Device: tissue adhesive (Leukosan®)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Wound discharge during stay

    The wound will be defined as actively oozing, if the standard bandage Mepilex Border Post-op®, is soaked to the border. Bandages soaked to the border will be replaced. Number of replaced bandages for each knee will be recorded.

    Measured: 3 days post op

Secondary outcomes (1)
  1. ASEPSIS score

    Wound healing score

    Measured: 3 weeks post op

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Sep 2017
  2. Study start1 Sep 2015
  3. Primary completion21 Dec 2017
  4. Study completion31 Dec 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Investigator
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03289247
Sponsor's protocol ID
HVH-SBTKA-Adhaesive
Status last verified
Jan 2019
First submitted
18 Sep 2017
Last updated
25 Jan 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing tissue adhesive (Leukosan®) in people with Total Knee Arthroplasty and Infection, run by Hvidovre University Hospital.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Jan 2019. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Wound discharge during stay (time frame: 3 days post op). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jan 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in